Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retigabine add-on therapy in adult refractory partial-onset seizures
CTR20160092Phase 3Suspended
- Sponsor
- Tianjin Hankang Pharmaceutical Biotechnology
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of retigabine in focal-onset epileptic seizures, sponsored by Tianjin Hankang Pharmaceutical Biotechnology. Started Sep 2017; status: suspended.
02
Drugs
retigabine
03
Conditions
focal-onset epileptic seizures
Beyond the preview
Go deeper on CTR20160092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160092.